Roche's anti-TIGIT drug suffers a phase III cancer setback

被引：6
|
作者：
Mullard, Asher
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2022年 / 21卷 / 05期
关键词：
D O I：
10.1038/d41573-022-00068-4
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：327 / 327
页数：1
相关论文
共 50 条
  • [1] Roche’s anti-TIGIT drug suffers a phase III cancer setback
    Asher Mullard
    Nature Reviews Drug Discovery, 2022, 21 (5) : 327 - 327
  • [2] Roche suffers HIV drug setback
    不详
    TCE, 2004, (752): : 16 - 16
  • [3] Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer
    Vaia Florou
    Ignacio Garrido-Laguna
    Current Oncology Reports, 2022, 24 : 1107 - 1112
  • [4] GSK to buy iTeos's anti-TIGIT antibody
    Satyanarayana, Megha
    CHEMICAL & ENGINEERING NEWS, 2021, 99 (23) : 11 - 11
  • [5] Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer
    Florou, Vaia
    Garrido-Laguna, Ignacio
    CURRENT ONCOLOGY REPORTS, 2022, 24 (09) : 1107 - 1112
  • [6] Promising New Anti-TIGIT Agents: Stealthy Allies in Cancer Immunotherapy
    Srikanth, Gatadi
    Beda, Durga Prasad
    Dwivedi, Ashish Ranjan
    Duddukuri, Nandan Kumar
    Nanduri, Srinivas
    Patel, Jitendra
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2025, 18 (04):
  • [7] Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer
    Wainberg, Z.
    Matos, I.
    Delord, J.
    Cassier, P.
    Gil-Martin, M.
    Kim, T.
    LoRusso, P.
    Bahleda, R.
    Italiano, A.
    Mendus, D.
    Hoang, T.
    Xue, C.
    Wen, X.
    Carvalho, O.
    Pham, T.
    Patil, N.
    Meng, R.
    Bendell, J.
    Cervantes, A.
    Cho, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S227 - S228
  • [8] Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials
    Attili, I.
    Passaro, A.
    de Marinis, F.
    ANNALS OF ONCOLOGY, 2022, 33 (02) : 119 - 122
  • [9] Phenotyping of TIGIT pathway members may be used for cancer selection in the clinical application of anti-TIGIT antibody EOS884448
    Wald, Noemie
    Cuende, Julia
    Mercier, Marjorie
    Nyawouame, Florence
    Brouwer, Margreet
    Houthuys, Erica
    Driessens, Gregory
    Bodo, Veronique
    Hoofd, Catherine
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [10] Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors
    Yamamoto, Noboru
    Koyama, Takafumi
    Sato, Jun
    Yoshida, Tatsuya
    Sudo, Kazuki
    Iwasa, Satoru
    Kondo, Shunsuke
    Yonemori, Kan
    Kawasaki, Atsuko
    Satake, Kyoko
    Shibata, Shoyo
    Shimizu, Toshio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (01) : 109 - 115
12345